Nucleic acids encoding mutant human CD80 and compositions...

Details Nucleic acids encoding mutant human CD80 and compositions... Nucleic acids encoding mutant human CD80 and compositions...

2000-04-27

2008-11-04

Ouspenski, Ilia (Department: 1644)

Organic compounds -- part of the class 532-570 series

Organic compounds

Carbohydrates or derivatives

C536S023100, C536S023500, C514S04400A, C435S091400

Reexamination Certificate

active

07446189

ABSTRACT:
Improved vaccines and methods of using the same are disclosed Immunosuppressive compositions for treating individuals who have autoimmune diseases or transplants and methods of using the same are disclosed.

REFERENCES:
patent: 4722848 (1988-02-01), Paoletti et al.
patent: 4736866 (1988-04-01), Leder et al.
patent: 4873191 (1989-10-01), Wagner et al.
patent: 4945050 (1990-07-01), Sanford et al.
patent: 5017487 (1991-05-01), Stunnenberg et al.
patent: 5036006 (1991-07-01), Sanford et al.
patent: 5077044 (1991-12-01), Stocker
patent: 5110587 (1992-05-01), Paoletti et al.
patent: 5112749 (1992-05-01), Brey, III et al.
patent: 5174993 (1992-12-01), Paoletti
patent: 5223424 (1993-06-01), Cochran et al.
patent: 5225336 (1993-07-01), Paoletti et al.
patent: 5240703 (1993-08-01), Cochran
patent: 5242829 (1993-09-01), Panicali et al.
patent: 5294441 (1994-03-01), Curtiss
patent: 5294548 (1994-03-01), Curtiss
patent: 5310668 (1994-05-01), Ellis et al.
patent: 5387744 (1995-02-01), Curtiss, III et al.
patent: 5389368 (1995-02-01), Curtiss, III
patent: 5424065 (1995-06-01), Curtiss, III et al.
patent: 5451499 (1995-09-01), Cochran
patent: 5453364 (1995-09-01), Paoletti
patent: 5462734 (1995-10-01), Letchworth, III et al.
patent: 5470734 (1995-11-01), Sondermeijer et al.
patent: 5482713 (1996-01-01), Paoletti
patent: 5580756 (1996-12-01), Linsley et al.
patent: 5589466 (1996-12-01), Felgher et al.
patent: 5593972 (1997-01-01), Weiner et al.
patent: 5739118 (1998-04-01), Carrano et al.
patent: 5830876 (1998-11-01), Weiner et al.
patent: 5837533 (1998-11-01), Boutin
patent: 5942607 (1999-08-01), Freeman et al.
patent: 6294660 (2001-09-01), Sharpe et al.
patent: 2004/0157296 (2004-08-01), Yang et al.
patent: 90/11092 (1990-10-01), None
patent: 93/17706 (1993-09-01), None
patent: 93/23552 (1993-11-01), None
patent: 94/16737 (1994-08-01), None
patent: WO 95/03408 (1995-02-01), None
patent: 95/26718 (1995-10-01), None
patent: 96/10038 (1996-04-01), None
patent: WO 96/11279 (1996-04-01), None
patent: WO 96/40915 (1996-12-01), None
Metzler et al., Nature Structural Biol., 1997, 4: 527-531.
Singh et al., Nature Biotechnology, 1999, 17: 1075-1081.
Selvakumar et al., “Genomic Organization and Chromosomal Location of the Human Gene Encoding The B-Lymphocyte Activation Antigen B7,”PubMed, 1992, abstract only.
Lanier et al., “CD80 (B7) and CD86 (B70) Provide Similar Costimulatory Signals for T Cell Proliferation, Cytokine Production, and Generation of CTL,”PubMed, 1995, abstract only.
Azuma et al., “ B70 Antigen is a Second Ligand for CTLA-4 CD28,”Nature, Nov. 4, 1993, vol. 366, pp. 76-79.
Freeman et al., “Structure, Expression, and T Cell Costimulatory Activity of the Murine Homologue Of the Human B Lymphocyte Activation Antigen B7,”J. Exp. Med., Sep. 1991, vol. 174, pp. 625-631.
Freeman et al., “A New Member of the Ig Superfamily with Unique Expression on Activated and Neoplastic B Cells,”The Journal of Immunology, Jul. 11, 1989, vol. 143, pp. 2714-2722.
Howell et al., “Limited T-Cell Receptor β-Chain Heterogeneity Among Interleukin 2 Receptor-Positive Synovial T Cells Suggests a Role for Superantigen in Rheumatoid Arthritis,”Proc. Natl. Acad Sci., Dec. 1991, vol. 88, pp. 10921-10925.
Kim et al., “Engineering of In Vivo Immune Responses to DNA Immunization Via Codelivery of Costimulatory Molecule Genes,”Nature Biotechnology, Jul. 15, 1997, vol. 15, pp. 641-646.
Oksenberg et al., “Limited Heterogeneity of Rearranged T-Cell Receptor Vα Transcripts in Brains of Multiple Sclerois Patients,”Letters to Nature, May 24, 1990, vol. 345, pp. 344-346.
Paliard et al., “Evidence for the Effects of a Superantigen in Rheumatoid Arthritis,”Science, Jul. 19, 1991, vol. 253, pp. 325-329.
Linsley et al., “Human B7-1 (CD80) and B7-2 (CD86) Bind with Similar Avidities but Distinct Kinetics to CD28 and CTLA-4 Receptors,”PubMed, Dec. 1994, vol. 1, No. 9, abstract only.
W. Williams, “Restricted Heterogeneity of T Cell Receptor Transcripts in Rheumatoid Synovium,”J. Clin. Invest., Aug. 1992, vol. 90, pp. 326-333.
Chaudhary et al., “A Rapid Method of Cloning Functional Variable-Region Antibody Genes inEscherichia colias Single-Chain Immunotoxins,”Proc. Natl. Acad. Sci., Feb. 1990, vol. 87, pp. 1066-1070.
K. Wucherpfennig, et al., “Shared Human T Cell Receptor VβUsage to Immunodominant Regions Of Myelin Basic Protein,”Science, 1990, vol. 248, pp. 1016-1019.
Gerstmayer et al., “Costimulation of T-cell Proliferation by a Chimeric B7-Antibody Fusion Protein,”Cancer Immunol Immunother, vol. 45, Nos. 3-4, pp. 156-158 (1997).
Fargeas et al., “Identification of Residues in the V Domain of CD80 (B7-1) Implicated in Functional Interactions with CD28 and CTLA4,”Journal of Experimental Medicine, Sep. 1, 1995, Tokyo, JP, vol. 182, pp. 667-675.
Peach et al., “Both Extracellular Immunoglobin-like Domains of CD80 Contain Residues Critical for Binding T-Cell Surface Receptors CTLA-4 and CD28”Journal of Biological Chemistry, American Society of Biological Chemists, Sep. 8, 1995, Baltimore, MD, vol. 270, No. 36, p. 1182, line 1-10, p. 21185-21186.
Inobe et al., “Identification of an Alternatively Spliced Form of the Murine Homologue of B7,”Biochemical and Biophysical Research Communications, Academic Press Inc., Apr. 15, 1994, Orlando, FL, vol. 200, No. 1, p. 446.
Morton et al., “Differential effects of CTLA-4 substitutions on the binding of human CD80 (B7-1) and CD86 (B7-2),”J Immunology(1996) 156:1047-1054.
Lanier et al., “CD80 (B7) and CD86 (B70) provide similar costimulatory signals for T cell proliferation, cytokine production and generation of CTL”, J. Immunol. vol. 154, No. 1, Jan. 1, 1995, pp. 97-105.
Linsley et al., “Human B7-1 (CD80) and B&-2 (CD86) bind with similar avidities but distinct kinetics to CD28 and CTLA-4 receptors”, Immunity vol. 1, No. 9, Dec. 1994, pp. 793-801.
Peach et al., “Both Extracellular Immunoglobulin-like Domains of CD80 Contain Residues Critical for Binding T Cell Surface Receptors CTLA-4 and CD28,” Journal of Biological Chemistry, vol. 270, No. 36, Sep. 8, 1995, pp. 21181-21187.
Inobe et al., “Identification of an Alternatively Spliced Form of the Murine Homologue of B7,” Biochemical and Biophysical Research Communications, vol. 200, No. 1, pp. 443-449.

Affiliated with

Also associated with

Rating

Nucleic acids encoding mutant human CD80 and compositions... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Nucleic acids encoding mutant human CD80 and compositions..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Nucleic acids encoding mutant human CD80 and compositions... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4030594